|
ORLANDO, FL -- 02/26/08 -- Cardiovascular Sciences, Inc. (PINKSHEETS:
CVSC), a corporation under the laws of Nevada and a client company
of the High Technology Incubator at the University of Central
Florida, is proud to announce that it has reached a partnership
agreement with Medical Technologies Enterprises, Inc. of Palm
Harbor, FL. Cardiovascular Sciences, Inc. is researching and
developing its proprietary technology designed to address a
need for a better and more effective product to prevent post-surgical
adhesions and its complications.
Medical Technologies Enterprises, Inc.'s founder and president,
Mr. Eric O. Edelmann, has extensive experience as a business
development consultant, serving many Fortune 500 companies
over more than 35 years. His firm, Strategic Futures International,
Inc., boasts many clients, ranging from the local companies
in the area up to global conglomerates. Medical Technologies
Enterprises, Inc. was founded as a retail enterprise to
market various proprietary and generic items, including
some medical supplies, various medical testing kits and as well
as an assorted array of supplements.
"We see several advantages to such a strategic partnership," explains
Cardiovascular Sciences, Inc.'s CEO, Dr. Larry Hooper. "Initially,
there will be an economy resulting from sharing many of the
administrative operations of the two companies. Second, it gives
us a retail presence in the marketplace and on the web. It is
seldom that a company, at this stage in the development of its
primary medical technology, has a revenue generating retail
market presence."
Similarly enthusiastic, Medical Technologies Enterprises, Inc.'s
Eric Edelmann exclaims, "This joint agreement gives both
companies a presence and access to the entire path from development
to market, from bench to bedside so to speak."
John Martin, who was recently appointed to the board of Cardiovascular
Sciences, Inc., has extensive experience with formulating and
marketing various supplement lines. "I see this as an excellent way to create and grow a significant
revenue stream at a very early stage. Additionally, it will diversify the company's
profit centers as Cardiovascular Sciences, Inc. continues to develop it's proprietary
medical technologies." Mr. Martin has a proven track record
in developing and marketing successful health enhancement strategies
and supplements.
Both companies are excited about the possibilities this represents
and the likely beneficial impact it will have, not just on the
near term financials, but also in the longer term as it allows
for an equity-sparing stepping up the pace of development of
Cardiovascular Sciences, Inc.'s anti-adhesion technology and
allows Medical Technologies Enterprises, Inc.'s access to and
early entry into markets with needs addressed by this technology
and other related technologies.
About Cardiovascular Sciences
Cardiovascular Sciences, Inc. is an advanced medical device
company which is developing a novel technology platform to address
the problem of post-surgical and post-traumatic adhesions. Adhesions
and the complications of adhesions are a significant problem
worldwide for a wide range of specialists, including general
surgeons, cardiothoracic surgeons, orthopedic, plastic, and
ophthalmologic and otolaryngology specialists to name just some
of them. In addition, the veterinary field has a tremendous
need for a product that can prevent similar problems in a wide
variety of animals.
The Company's unique materials and processes promise a more cost-effective
and decidedly more efficient and capable means to deal with a problem
that has been so devastating to so many. Current
sponsored research at the University of Central Florida (UCF)
and previously at other institutions indicate that The Company
is on the right path and progressing well.
In addition to the anti-adhesion technology, The Company owns
technology in a variety of other areas, including thrombo-resistant
coatings, enhanced intra-arterial balloon pumping catheters,
cell engineered vascular tissues, and a method for improved
recovery of the heart following cardioplegia. This yields a
diversified portfolio with projects in various stages of development. www.cvsciences.org
Forward-looking statements in this release are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject
to certain risks, and uncertainties and actual results could
differ from those discussed. This material is information only
and is not an offer or solicitation to buy or sell the securities.
For more information contact:
Cardiovascular Sciences Investor Relations
800-858-7502
ir@cvsciences.org |
